BPI-9016M, a novel c-Met inhibitor, in pretreated advanced solid tumor: Results from a first-in-human, phase I, dose-escalation study.

被引：0
|
作者：
Hu, Xingsheng
Zheng, Xin
Mo, Hongnan
Cui, Xinge
Ding, Lieming
Tan, Fenlai
Hu, Pei
Shi, Yuankai
机构：
[1] Chinese Acad Med Sci, Beijing Key Lab Clin Study Anticancer Mol Targete, Canc Hosp, Natl Canc Ctr, Beijing, Peoples R China
[2] Peking Union Med Coll, Beijing, Peoples R China
[3] Peking Union Med Coll Hosp, Peking Union Med Coll, Clin Pharmacol Res Ctr, Beijing, Peoples R China
[4] Chinese Acad Med Sci, Beijing, Peoples R China
[5] Peking Union Med Coll Hosp, Beijing, Peoples R China
[6] Betta Pharmaceut Co Ltd, Hangzhou, Zhejiang, Peoples R China
[7] Peking Union Med Coll Hosp, Clin Pharmacol Res Ctr, Beijing, Peoples R China
[8] Chinese Acad Med Sci, Beijing Key Lab Clin Study Anticancer Mol Targete, Canc Hosp, Dept Med Oncol,Natl Canc Ctr, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e21108
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21108
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies
    A Spreafico
    J-P Delord
    L De Mattos-Arruda
    Y Berge
    J Rodon
    E Cottura
    P L Bedard
    M Akimov
    H Lu
    S Pain
    A Kaag
    L L Siu
    J Cortes
    British Journal of Cancer, 2015, 112 : 650 - 659
  • [42] A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies
    Spreafico, A.
    Delord, J-P
    De Mattos-Arruda, L.
    Berge, Y.
    Rodon, J.
    Cottura, E.
    Bedard, P. L.
    Akimov, M.
    Lu, H.
    Pain, S.
    Kaag, A.
    Siu, L. L.
    Cortes, J.
    BRITISH JOURNAL OF CANCER, 2015, 112 (04) : 650 - 659
  • [43] Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer
    Shitara, Kohei
    Kim, Tae Min
    Yokota, Tomoya
    Goto, Masahiro
    Satoh, Taroh
    Ahn, Jin-Hee
    Kim, Hyo Song
    Assadourian, Sylvie
    Gomez, Corinne
    Harnois, Marzia
    Hamauchi, Satoshi
    Kudo, Toshihiro
    Doi, Toshihido
    Bang, Yung-Jue
    ONCOTARGET, 2017, 8 (45) : 79546 - 79555
  • [44] First-in-human study of HMPL-295, an ERK1/2 inhibitor, in patients with advanced solid tumors: Dose-escalation results of monotherapy
    Yu, Xianjun
    Zhang, Jian
    Sun, Yuping
    Deng, Yanhong
    Guo, Shuangshuang
    Hong, Wei
    Shi, Si
    Liu, Rujiao
    Gao, Shuiping
    Dang, Qi
    Zhang, Jianwei
    Su, Weiguo
    Shi, Michael
    Fan, Songhua
    Zhang, Bo
    Pan, Beiqing
    Jia, Xiaoyun
    Wang, Jian
    Zhong, Chen
    Ma, Luguang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] Dose escalation results from a first-in-human study of ABBV-400, a novel c-Met-targeting antibody-drug conjugate, in advanced solid tumors
    Sharma, Manish
    Kuboki, Yasutoshi
    Camidge, D. Ross
    Perets, Ruth
    Sommerhalder, David
    Yamamoto, Noboru
    Bar, Jair
    Parikh, Apurvasena
    Li, Rui
    Thiele, Gladys Morrison
    Aristide, Martha Raluca Neagu
    Freise, Kevin Jay
    Powderly, John D.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] First-in-human phase I study of a selective c-Met inhibitor volitinib (HMP504/AZD6094) in patients with advanced solid tumors
    Gan, Hui Kong
    Lickliter, Jason
    Millward, Michael
    Gu, Yi
    Su, Weiguo
    Frigault, Melanie
    Qi, Chuan
    Mu, Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [47] MSC2156119J (EMD 1214063), an oral selective c-Met inhibitor, in patients with advanced solid tumors: results of the first-in-human phase I trial
    Falchook, Gerald S.
    Hong, David S.
    Amin, Hesham M.
    Fu, Siqing
    Piha-Paul, Sarina Anne
    Janku, Filip
    Granda, J. Gabrielle
    Zheng, HongXia
    Klevesath, Manfred B.
    Koehler, Karola
    Bladt, Friedhelm
    Johne, Andreas
    Kurzrock, Razelle
    CANCER RESEARCH, 2014, 74 (19)
  • [48] First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors
    Keedy, Vicki L.
    Lenz, Heinz-Josef
    Saltz, Leonard
    Whisenant, Jennifer G.
    Berlin, Jordan D.
    Camacho, Luis H.
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (05) : 860 - 868
  • [49] A phase 1, dose-escalation, first-in-human study of ARQ 087, an oral pan-FGFR inhibitor, in adult subjects with advanced solid tumors
    Papadopoulos, K.
    Tolcher, A.
    Kittaneh, M.
    Patniak, A.
    Rasco, D.
    Chambers, G.
    Newth, G.
    Savage, R.
    Hall, T.
    Schwartz, B.
    Kazakin, J.
    LoRusso, P.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 125 - 125
  • [50] First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors
    Vicki L. Keedy
    Heinz-Josef Lenz
    Leonard Saltz
    Jennifer G. Whisenant
    Jordan D. Berlin
    Luis H. Camacho
    Investigational New Drugs, 2018, 36 : 860 - 868
12345